HopeStage
Back to all studies
CompletedEUCTR 2017-000990-35

EFFECTS OF ANTIDEPRESSANT TREATMENT WITH AGOMELATINE ON PATIENTS AFFECTED BY DEPRESSION AND EPILEPSY. A DOUBLE BLIND RANDOMIZED STUDY WITH ACTIVE CONTROL (ESCITALOPRAM) WITH PARALLEL GROUPS.

This historical record does not confirm current site availability.

Historical research recordItaly
The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations
Italy
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
208
Sponsor
DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Italy
Age range
Not clearly listed
Official registry ID
EUCTR 2017-000990-35
Official title
Show the full official title

EFFECTS OF ANTIDEPRESSANT TREATMENT WITH AGOMELATINE ON PATIENTS AFFECTED BY DEPRESSION AND EPILEPSY. A DOUBLE BLIND RANDOMIZED STUDY WITH ACTIVE CONTROL (ESCITALOPRAM) WITH PARALLEL GROUPS.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Italy

Registry details
Historical country statuses

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA.

Want to explore more studies?

Explore studies